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Summary The intrinsic radiosensitivity of cervical carcinoma has been measured using a soft agar clonogenic
assay. All patients received radical radiotherapy alone with a minimum of 2 years post-treatment follow-up.
Only women with stage I, II and III disease were included in the analysis. Values for cell surviving fraction at
2 Gy (SF2) were obtained for 88 tumours with an assay success rate of 73%. The 53 patients alive and well at
the time of analysis had tumours with a mean SF2 that was significantly lower than the value from the 22
patients with locoregional failure (P< 0.01). Patients with radioresistant tumours (SF2> 0.40, the median) had
a significantly lower 3 year survival level than those with sensitive tumours (SF2 <0.40) (P = 0.002). Also the
frequency of local recurrence was higher (P = 0.001) whether these were central (P = 0.009) or peripheral
(P = 0.046). Cell surviving fraction at 3.5 Gy was obtained for 46 tumours and the 3 year patient survival rate
was significantly higher for those with SF3.5 values less than the median (P = 0.043). There was, however, no
difference in the level of local recurrence (P = 0.24). The ability to grow in culture was not associated with
significantly poorer patient survival (P = 0.56) or failure to control the primary disease (P = 0.17). While high
colony forming efficiencies were associated with an increased rate of local recurrence (P = 0.029) they did not
predict for overall patient survival (P = 0.32). These data suggest that, for cervical carcinoma treated with
radical radiotherapy, intrinsic radiosensitivity is important in determining treatment outcome.
A number of laboratory-based potential prognostic factors
for the radiotherapy of cancer are under investigation. Of
particular interest are tumour oxygenation (Hockel et al.,
1993), proliferation (Begg et al., 1990) and radiosensitivity
(Peters & Brock, 1992). One or some of these may eventually
enable the prediction of treatment response and would thus
provide a useful tool in the planning of patient care. Such
individualisation of therapy should ultimately lead to im-
provements in the survival figures for patients with various
cancers and reduce treatment morbidity.
Recent interest in assays of radiosensitivity stems from the
reports of a correlation between the ability to control various
classes of tumour and parameters that describe the initial
portion of cell survival curves derived from the tumours
(Malaise et al., 1987). These parameters are surviving frac-
tion at 2 Gy (SF2), the initial slope (a) and the mean inactiva-
tion dose (D, the integral of fitted curves). Experimental
studies have subsequently supported these observations and
shown that, in animal models, SF2, measured in vitro, can
predict response to in vivo irradiation (reviewed in West &
Hendry, 1992).
A number of projects have now been set up to evaluate the
usefulness of pre-treatment assessments of intrinsic radiosen-
sitivity. Our own correlations of SF2 with early outcome
following radiotherapy in cervical cancer have been encour-
aging (West et al., 1989; 1991a; 1992). In addition, preliminary
results are emerging from work being carried out using the cell
adhesive matrix (CAM) assay on squamous cell carcinomas
(head and neck, cervix) treated predominantly by radiotherapy
alone. These also suggest that measurements of intrinsic radio-
sensitivity can predict response to treatment (Grinsky et al.,
1992). In contrast a study using the CAM assay on advanced
head and neck cancers treated by postoperative radiotherapy
has yielded less favourable results (Brock et al., 1992).
This report is an update on radiosensitivity testing studies
carried out at the Christie Hospital in Manchester. The work
is an investigation into the ability of SF2, measured using the
Courtenay-Mills soft agar assay, to predict patient outcome
for stage I -III carcinoma of the cervix treated with
radiotherapy alone. All patients have had a minimum of 2
years follow-up.
Materials and methods
Patients
Tumour biopsies were taken under anaesthetic from patients
with proven carcinoma of the cervix, immediately prior to
treatment with radiotherapy. Parallel specimens were sent to
histopathology for assessment of the histological type and
grade. All patients included in the analysis were treated
radically using the techniques and dosage schedules of the
Manchester School (Hunter, 1991). Patients with small
volume stage Ib or Ila disease were treated with intra-
cavitary low dose rate caesium alone with two insertions
giving an A point dose of 67.5-75 Gy. Remaining patients
either received external beam irradiation (small-field, wedged
inhomogeneous 16 fractions in 3 weeks giving 32.5 Gy to
point B) followed by two intra-cavitary caesium insertions (A
point dose of 50-60 Gy) or external beam to large box fields
over 4 weeks (40-45 Gy homogeneously) supplemented by a
single low dose rate intra-cavitary insertion (A point dose of
22.5-37.5 Gy).
Follow-up schedules of 3 monthly in the first 2 years, 4
monthly in the third year and 6 monthly for the last 2 years
were employed. The median follow-up time was 39 months
(range 24-56). Women suspected of pelvic recurrence within
the radiation field were re-assessed and the recurrence
confirmed histologically and/or using radiological techniques.
The recurrences were divided into central (i.e. central pelvic
recurrence) and peripheral (i.e. those occurring at the edge of
the radiation field). Recurrence on the pelvic sidewall was
taken as peripheral for external beam irradiated tumours or
as metastatic disease for those treated solely with intra-
cavitary irradiation.
Tumour disaggregation
The tissue was minced and placed in basal medium Eagle's
(Gibco, Paisley, Scotland; 50 ml per 0.5 g) supplemented with
20 glg ml-' amphotericin (Sigma, Poole, UK), 200 pg ml-'
gentamicin (Sigma), 15 mM Hepes (Gibco), 0.5 mg ml-'
pronase (Boehringer, Germany), 0.5 mg ml-' collagenase
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(Sigma) and 0.4 mg ml1 deoxyribonuclease I (Sigma). After
1.5 h at 37°C in a shaking water bath, the supernatant was
collected and placed on ice while the specimen was digested
for a further 0.5 h with 0.05% trypsin (Worthington Diag-
nostics Ltd, Freehold, New Jersey, USA; 50 ml per 0.5 g).
Following disaggregation the tumour material was filtered,
washed and resuspended in growth medium (Ham's F12
(Gibco) plus 15% foetal calf serum (Biological Industries),
2 pg ml-' amphotericin, 25 pg ml-' gentamicin, 10 ng ml-'
epidermal growth factor (Sigma), 10 fig ml-' insulin (Col-
laborative Research), 0.5 fig ml-' hydrocortisone (Sigma) and
2.5 jig ml-' transferrin (Sigma)). The resulting cell suspension
was filtered through a 37 lim screen and a viable cell count
obtained (trypan blue-exclusion).
Clonogenic assay
Clonogenicity was determined using the Courtenay-Mills soft
agar assay (Courtenay & Mills, 1978; Wilks & West, 1991).
Tumour single-cell suspensions (0.5 ml at ten times the
required concentration) and 0.5 ml of 1 in 8 diluted August
rat (Harlan Olac, Bicester, Oxon, England) red blood cells
(diluted in Ham's F12) were mixed with 4 ml 0.5% noble
agar (Difco, Detroit, MI, USA) in growth medium. Aliquots,
1 ml, were dispensed into tubes and incubated in a
humidified atmosphere of 5% 02, 5% CO2 and 90% N2.
Four to eight replicates were set up for each of 1-3 dilution
points. Cultures were fed weekly and after 4 weeks stained
with iodonitrotetrazolium violet (0.2 ml of a 0.5 mg ml-'
solution; Sigma) Colonies >60 ym in diameter (i.e. with
>50 cells) were counted using a semi-automated image
analysis system (MOP videoplan, Kontron, Watford, Herts,
England). Colony forming efficiency (CFE) was calculated as
the number of colonies formed divided by the total number
of viable nucleated cells plated and expressed as a percentage.
Intrinsic radiosensitivity
Intrinsic radiosensitivity was determined as sensitivity to a
single in vitro dose of radiation, surviving fraction at 2 Gy
(SF2). Irradiations were carried out prior to plating at room
temperature using a '37Cs gamma-ray source with a dose rate
of 3.8-4.2 Gy min-'. Larger cell suspensions were irradiated
also with 3.5 and 10 Gy and the latter served as a control to
check for the absence of cell clumps.
Statistical analysis
Values for SF2 appeared to be normally distributed (David-
son et al., 1990). Two sample t tests were, therefore, used to
test for the level of significance of differences between data
sets. The probabilities of locoregional control and overall
patient survival were determined using logrank analysis, with
the continuous variables grouped into two or four bands.
The group boundaries corresponded to the quartiles or
median, giving equal sized groups. Missing values and values
falling exactly on the group boundaries (taken with the lower
values i.e. SF2 <0.40, SF3.5 <0.17, CFE <0.06%) meant that,
in practise, the data subsets were not exactly the same size.
tumours with the other being stage Ila. The viable cell yield
was adequate in 3/7 (i.e. > 3.3 x 106 cells per gram), one cell
suspension contained cell clumps and the remaining three
tumours produced poor cell yields. Clonogenic growth (a
minimum of an average of ten colonies per tube at the
highest plated cell density) was obtained in 118 (79%) of the
remaining 149 and there were three (2%) infected cultures.
Values for SF2 were obtained in only 105 (73%) of these due
to low cell yields. Only 88 of these were used, as patients
treated palliatively (8), and those with stage IV disease (5) or
metastatic tumours (4) were excluded from the analysis. The
average biopsy weight of the 88 tumours was 0.46 g (range
0.04-3.13) with an average viable cell yield following dis-
aggregation of 2.5 x I07 cells per gram (range [0.004-11.2] x
107).
A cumulative frequency curve for the 88 SF2 values is
shown in Figure 1. Patients were divided into groups for
those: alive-and-well, with recurrent disease, central recur-
rences, peripheral recurrences or metastatic disease only. A
proportion of local failures were also metastatic. Table I lists
the mean SF2 values obtained for the various groups.
Patients alive-and-well at the time of analysis had tumours
with a mean SF2 value of 0.38 which was significantly lower
than the value from patients who failed locally (SF2 = 0.54;
P<0.01) whether this was centrally (SF2 = 0.55, P = 0.02) or
at the edge of the radiation field (SF2 = 0.53, P = 0.01).
Patients with only metastatic disease had tumours with an
average SF2 of 0.43 which was not significantly different from
either the disease-free (P= 0.39) or recurrence (P>0.10)
groups.
The ability of SF2 measurements to predict treatment out-
come is illustrated in Figure 2 where the SF2 values have
been stratified into two halves. Patients (20 dead/42) with
radioresistant tumours had a significantly lower 3 year sur-
vival rate than those (7 dead/46) with sensitive tumour cells
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Figure 1 A cumulative frequency graph of the SF2 values from
88 cervix tumours. Arrows above and below the data indicate
patients who died of respectively central and peripheral local
recurrence. A line is drawn across the median.
Results
Validation of the Courtenay-Mills assay used in this study
has been reported previously. Preliminary work demonstrated
the malignant epithelial origin of the colonies (Davidson et
al., 1992), linearity of colony number with cells plated, the
ability to produce radiation survival curves, that intra-
tumour heterogeneity was not a limitation to measurements
of SF2 and that there were statistically significant differences
in the radiosensitivity of individual tumours (West et al.,
1989; Davidson et al., 1990).
Over a 56 month period 156 tumours were received. There
was insufficient material following disaggregation in 7. These
specimens all weighed less than 0.1 g and 6 were stage lb
Table I Intrinsic radiosensitivity, measured as mean cell surviving
fraction at 2 Gy (SF2) for patients with a minimum of2 years follow-up
after treatment with radical radiotherapy alone. They have been divided
into groups for those alive and well, dead/with recurrent disease (either
central or peripheral) and dead of/with metastases only. The P values
refer to the results of t test comparisons with the alive-and-well data
n SF2
Alive-and-well 53 0.38
Recurrence 22 0.54 P<0.01
Central recurrence 11 0.55 P = 0.02
Peripheral recurrence 11 0.53 P = 0.01
Metastasis 13 0.43 P = 0.39RADIOSENSITIVITY IN CERVIX TUMOURS 821
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Figure 2 Survival (a,b) and local control (c,d) vs SF2. The data
from 88 patients have been stratified according to the median
(a,c) or 4 quartiles (b,d).
(P= 0.002). Also the frequency of local recurrence was
higher (17/42 vs 5/46; P = 0.001) whether these were central
(9/42 vs 2/46; P= 0.009) or peripheral (8/42 vs 3/46;
P= 0.046). The SF2 values were also divided into four quar-
54 tiles (Figure 2). Patient survival decreased with increasing
tumour cell radioresistance with 4/22, 3/24, 8/21 and 12/21
deaths in the four quartiles. While the number of patients
with local recurrence increased with 3/22, 2/24, 6/21 and
11/21 locoregional failures.
For the data set analysed, stage alone was a poorer predic-
30 tor of patient outcome (Figure 3). The 3 year survival levels
were 88, 57 and 62% for stage I, II and III disease respec-
tively and the trend for poorer survival with increasing stage
was significant (P= 0.023). However, tumour stage was a
poor prognostic factor for the probability of local failure
(P= 0.28), indicating it to be a better predictor of the
likelihood of metastatic spread (i.e. nodal disease). The
54 predictive potential of SF2 measurements for the individual
stages was also examined (Figure 4). The number of local
failures for the SF2 <0.40 and SF2>0.40 groups respectively
were 1/18 and 5/14 - stage I, 3/18 and 6/17 - stage II and
1/10 and 6/11 - stage III disease. Neither tumour grade nor
patient age influenced survival or the ability of radiotherapy
to control locoregional disease (P>0.73). The patients were
so divided into two groups for those above and below the
median age of 50. SF2 predicted local recurrence for the
younger age group only (Figure 5). However because of the
numbers involved, the difference between the two age groups
was not significant and after allowing for SF2, age was not a
significant prognostic factor (P = 0.40).
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Figure 3 Survival and local control vs tumour stage. There were 32, 35 and 21 patients respectively with stage I, II and III disease.
Values in brackets indicate the number of patients in each arm.
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Figure 4 Local control vs SF2 for stage I, II and III tumours. The upper arms are SF2 < 0.40 and the lower arms are SF2> 0.40.
Values in brackets indicate the number of patients in each arm.
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Figure 5 Local control vs SF2 for patients less than or greater than the median age of 50. The upper arms are SF2 < 0.40 and the
lower arms are SF2>0.40. Values in brackets indicate the number of patients in each arm.
Surviving fraction at 3.5 Gy (SF3.5) was obtained for 46
tumours (Table II). The 3 year survival rate was significantly
higher for patients with SF3.5 values less than or equal to the
median of 0.175 (19/23 vs 13/23; P = 0.043). However there
was no difference in the level of local recurrence with five and
eight recurrences in the sensitive and resistant bands respec-
tively (P = 0.24).
The ability to grow, in culture was investigated for 119
patients, which included 21 patients whose tumours failed to
meet the criterion for growth in culture and ten patients for
whom CFE only was obtained. For this larger data set, stage
at presentation was important in determining both survival
(P<0.001) and local failure (P = 0.005). For the no growth
group, five or 21 patients died, two of local recurrence. While
for the growth set, 31 of 98 patients died, 24 of local recur-
rence. Despite the weak trend for patients with tumours that
grew in culture to respond better to treatment, the difference
was not significant for either survival (P = 0.56) or failure to
control the primary disease (P = 0.17). However, the ability
to grow in culture showed a correlation with clinical stage;
14/52 stage I tumours did not grow compared to 7/67 stage
II and III tumours (P = 0.036; X2 test).
High CFEs (greater than the median of 0.06%) were
associated with an increased rate of local recurrence (15/42 vs
7/46; P = 0.029) but only for those occurring in the centre
(9/42 vs 2/47; P = 0.014) rather than at the periphery (5/46 vs
6/42; P = 0.53) of the radiation field. CFE did not predict for
overall survival with 63% 3 year survival in the high and
71% in the low CFE groups (P = 0.32).
Discussion
Using the Courtenay-Mills assay clonogenic growth was
obtained in 79% of the tumour specimens. Although the
success rate for measuring SF2 was only 73%, this could be
increased if larger biopsies were taken as in this study only
half of each tumour specimen was available. The overall
success rate for obtaining SF2 values was 88/139 (63%). This
would not be a limitation to radiosensitivity testing if the
ability of a tumour specimens to grow in culture was
associated with an increased level of local recurrence and
lower rates of survival. Although these trends were observed,
Table II A summary of the patient ages, tumour colony forming
efficiency (CFE), and tumour intrinsic radiosensitivity measured as
surviving fraction at 2 (SF2) or 3.5 (SF3.5) Gy
n Mean Median Range
Age (years) 88 51 49 26-78
CFE (%) 88 0.130 0.060 0.007-1.21
SF2 88 0.43 0.40 0.14-0.92
SF3.5 46 0.185 0.175 0.013-0.49
the differences in survival/local control between the growth
and no-growth groups were not significant. This supports the
work of others which has shown that patients whose in vitro
cell cultures failed did not fare significantly better than those
for whom successful cell cultures were obtained (Girinsky et
al., 1992). However, there was a significant correlation
between growth potential and stage with a higher proportion
of stage I compared to stage II and III tumours failing to
grow well in culture. High CFEs were associated with a
significant increase in local recurrence rates but did not
predict survival and the latter finding confirms a previous
report by us on a smaller group of patients (Davidson et al.,
1992).
The correlation between SF2 and failure to control local
disease agrees with our earlier reports on smaller data sets
(West et al., 1991a,b). A similar result has recently been
described by Girinsky and co-workers using the CAM assay
on a mixed group of head and neck and cervix tumours
(Girinsky et al., 1992). In contrast, another large study using
the CAM assay on head and neck cancers treated with
radiotherapy plus surgery has failed to show a significant
correlation between intrinsic radiosensitivity and treatment
outcome (Brock et al., 1992). This may be because SF2 (or a)
will be a better predictor for patient outcome following
radiotherapy alone rather than when combined with surgery.
Alternatively it may reflect the different proportions of the
various disease sites included in the analyses, with for
example 69% (Girinsky et al., 1992) vs 22% (Brock et al.,
1992) oropharynx tumours in the two studies. Use of the
CAM assay has been criticised due to its failure to suppress
fibroblast growth (Parkins & Steel, 1990). However, the
results of Girinsky and co-workers (1992) support its use in
clinical studies. As the CAM is more rapid than the
Courtenay-Mills assay used in this work, the results of its use
in cervix cancers treated with radiotherapy alone will be of
interest.
In this study, for the larger tumour specimens obtained,
radiosensitivity was also assessed as SF3.5. Although this was
carried out as an experimental check to ensure that SF3.5
values were lower than those at 2 Gy, it was of interest to
evaluate the ability of SF3.5 to predict patient outcome. Using
published radiation cell survival curves, the capacity of sur-
vival levels to discriminate between groups of tumours
differing in clinical radiocurability has been shown to be dose
dependent between 1 and 6 Gy. The relationship showed a
bell-shaped curve with a peak between 1.5 and 2 Gy (Malaise
et al., 1987). The results reported here show that, for the
small numbers of tumours examined, SF3.5 values did not
predict for local recurrence although they did predict for
overall survival (P = 0.043). Therefore, these clinical data
support the observations made using cell lines that SF3.5 is
less effective than SF2 in predicting radiocurability.
The predictive potential of measurements of SF2 was inves-
tigated separately for stage I, II and III disease. Although the
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same trend was seen for all disease stages the results were
only significant for stage III disease. It may be that intrinsic
radiosensitivity is more important for bulkier tumours. How-
ever larger numbers of patients need be accrued before any
definite conclusions can be drawn. For the data set analysed,
stage alone was poorer than SF2 at predicting patient out-
come. This may be partly explained by the size of the
tumours obtained. All stage I tumours were classified as lb
and many were bulky tumours. It should be noted that for
small tumours there would be insufficient material available
for cell cultures to be carried out. This is supported by the
observation of a higher than expected level of local recur-
rence for stage I carcinoma of the cervix.
The importance of age in carcinoma of the cervix has not
been clearly defined. Although there are some reports of a
poorer prognosis for younger patients (e.g. Elliot et al., 1989)
others have shown the opposite (e.g. Russell et al., 1987). For
the group of patients analysed as part of this study, age was
not a significant prognostic factor, either alone or after
allowing for SF2. However, an interesting trend of the data
was the observation that SF2 may have more value in
younger patients. As with the other subsets analysed more
numbers must be accrued before firm conclusions can be
drawn. Nevertheless, if the finding can be verified with larger
patient numbers then they may suggest a possible hormonal
influence with perhaps intrinsic radiosensitivity being more
important for pre-menopausal women. If this proves to be
the case then, as there was no difference in treatment out-
come between patients older or younger than the median age,
some other factor must be dominating response to radio-
therapy for the older women.
There are a number of radiobiological parameters that
would be expected to influence radiotherapy treatment out-
come. A mathematical study concluded that predictive assays
based on estimates of intrinsic tumour cell radiosensitivity
are likely to be more accurate in predicting tumour response
than assays based on clonogen doubling time, extent of
hypoxia or clonogen number (Tucker & Thames, 1989). For
the patients analysed as part of this report, five with
radiosensitive tumours recurred locally. Of these five, two
had values for CFE that fell well above the median (0.23 and
0.66%). Another with a CFE just above the median was a
bulky tumour (5 x 5 x 6 cm). This tumour also had a high
Ki67 index (.301 compared to a median of .190; S. Glew,
personal communication) suggesting a high rate of tumour
proliferation. It is likely that the future of predictive testing
lies in the assessment of multiple parameters which include
measures of radiosensitivity, hypoxia, proliferation and
maybe even clonogen number. For this to be feasible on a
routine basis assays are required that are not only rapid and
reliable but also either require just a small amount of tissue
or are non-invasive.
In conclusion these results support the idea that intrinsic
radiosensitivity influences response to radiotherapy partic-
ularly in large tumours. They also suggest that in vitro
measurements of SF2 can predict patient outcome for cervical
carcinoma treated with radiotherapy alone. These findings
should also encourage the development of alternative assays
for radiosensitivity testing that are rapid, reliable and feasible
for large scale routine clinical use.
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